RBC Capital analyst Gregory Renza maintained a Buy rating on BELLUS Health (BLU - Research Report) on November 14 and set a price target of $21.00. The company's shares closed yesterday at $9.39.According to TipRanks, Renza is an analyst with an average return of -1.5% and a 35.48% success rate. Renza covers the Healthcare sector, focusing on stocks such as Amgen, Jazz Pharmaceuticals, and Seagen.The word on The Street in general, suggests a Strong Buy analyst consensus rating for BELLUS Health with a $20.01 average price target, implying an 113.10% upside from current levels. In a report released yesterday, H.C.
https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-bellus-health-blu?utm_source=advfn.com&utm_medium=referral
Blue Chip Value Fund, Inc. (NYSE:BLU)
Historical Stock Chart
From Mar 2023 to Apr 2023 Click Here for more Blue Chip Value Fund, Inc. Charts.
Blue Chip Value Fund, Inc. (NYSE:BLU)
Historical Stock Chart
From Apr 2022 to Apr 2023 Click Here for more Blue Chip Value Fund, Inc. Charts.